Erlotinib (Tarceva®) and gefitinib (Iressa®), EGFR tyrosine kinase inhibitors (TKIs), have been developed and widely used for treatment of NSCLC patients, yet their effectiveness was limited to the selected population of patients with EGFR abnormalities3. This evidence concerns the gene EGFR and non-small cell lung carcinoma.